



IOptima (Subsidiary) : Approval to register a patent in Canada

Tel Aviv (Sep 6, 2018) – BioLight is pleased to announce that today, its subsidiary IOptima Ltd., ("**IOptima**")¹, announced it has received approval to register a patent from the Canadian Patent Office (the "**Patent**").

The Patent, owned by IOptima, is designed to protect the core technology of the IOptiMate™ system and its activity on the eye, for the purpose of a non-invasive procedure for the treatment of glaucoma. The expiry date of the Patent, after its registration, is December 31, 2029.

Said Patent approval joins additional patents of Optima in other territories worldwide, including in the USA, Europe, Israel, China, Japan, India and South Africa, thereby strengthening its intellectual property and competitive position. The completion of registration of the Patent is subject to the payment of fee, as customary.

¹ After completing the first phase of the investment and purchase agreement with the Chinese pharmaceutical company (the "**Agreement**"), BioLight holds, via XL Vision Sciences Ltd., 57% of the issued and share capital of IOptima (approximately 55% in full dilution). For additional information regarding the Agreement, please see Biolight's report of March 29, 2018.